ASX ANNOUNCEMENT **6 May 2025**

LODGEMENT OF CONNEQT PULSE DEVICE WITH THE TGA

Cardiex Limited (ASX: CDX) (the **Company**), is pleased to announce the formal lodgement of its application with the Therapeutics Goods Administration (TGA) for the inclusion of the FDA-cleared CONNEQT Pulse device (Pulse) in the Australian Register of Therapeutic Goods (ARTG).

This follows the recent finalisation of a Market Agreement between Cardiex and manufacturing partner, Andon, to complete the necessary regulatory requirements in Australia. With the TGA lodgement now complete, the Company is well positioned to achieve inclusion in the ARTG.

Cardiex CEO Craig Cooper commented:

"With FDA clearance in the United States and now a formal TGA lodgement in Australia, we are establishing a strong global footprint for the CONNEQT brand. We are excited to bring our transformative cardiovascular technology to new markets and help drive better health outcomes worldwide."

The Company will continue to keep shareholders informed as further regulatory and commercial milestones are achieved. The TGA registration process is expected to take approximately three to six months.

Approved by the Board of Directors and Released by the Company Secretary

- ENDS -

For more information, please contact:

Investor Relations
Rod Hinchcliffe
rod.hinchcliffe@mcpartners.com.au

Media Relations
Melissa Hamilton
melissa.hamilton@mcpartners.com.au

About Cardiex

Cardiex's mission is to increase longevity through medical technology advancements in vascular health. The Company's suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders - all based on the Company's market leading SphygmoCor® vascular biomarker technology. Cardiex is listed on the Australian Stock Exchange ("ASX:CDX").